Quarterly report · Q2
4078.TEDINET S100PH2A
Period2022-04-01 → 2022-09-30
Filed2022-11-09
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥42.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥80.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥39.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥3.3bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥4.4bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥3.8bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥8.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.6bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥4.2bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥4.5bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.9bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥6.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.2bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.0bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥3.3bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥128.4bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥123.9bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥124.5bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥42.6bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥41.2bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥85.8bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥82.7bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥82.3bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥11.9bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.8bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥11.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.8bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.2bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥6.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.4bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥177.48 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.08 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥407.06 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥188.85 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥91.63 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 63.6% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.2% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥860m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥860m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥1.1bn |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥39.3bn |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥38.6bn |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥697m |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.1bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥163m |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥240m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥43.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥42.7bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥860m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥4.4bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥684m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥684m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥977m |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥36.4bn |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥35.8bn |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥548m |
| jpcrp040300-q2r_E00780-000Chemicalreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥5.1bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥4.1bn |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥136m |
| jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥233m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥40.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥39.9bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥684m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥5.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 510
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |